Stryker Corporation (SYK): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Stryker Corporation ( SYK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 2.0%. By the end of trading, Stryker Corporation rose $1.84 (2.2%) to $84.13 on average volume. Throughout the day, 2,429,574 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1,682,600 shares. The stock ranged in a price between $82.34-$84.23 after having opened the day at $82.54 as compared to the previous trading day's close of $82.29. Other companies within the Health Care sector that increased today were: Response Genetics ( RGDX), up 18.3%, Catalyst Pharmaceutical Partners ( CPRX), up 8.6%, ProPhase Labs ( PRPH), up 7.9% and Edap TMS ( EDAP), up 6.3%.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. Stryker Corporation has a market cap of $31.0 billion and is part of the health services industry. Shares are up 9.5% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Stryker Corporation a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, BG Medicine ( BGMD), down 17.7%, Venaxis ( APPY), down 15.5%, Akebia Therapeutics ( AKBA), down 12.5% and Celladon ( CLDN), down 12.4% , were all laggards within the health care sector with Amgen ( AMGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug